Autopsy report · NCT00442507

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

“Slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 10 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 6 years 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Washington University School of Medicine

Sponsor type

University, hospital or other

Conditions

Esophageal Neoplasms; Esophageal Diseases

Interventions

Erlotinib; Avastin

Participants

6

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.